Table 1 Summary of Treatment Received for Patients in Case Series
Primary Diagnosis | Systemic treatment received before ICI (best response, progression free survival) | ICI received (best response, progression free survival) | Systemic treatment received post ICI (best response, progression free survival) |
|---|---|---|---|
Case 1 HCC (uninfected) | Sorafenib (SD, 17.3 weeks) | PD-1 inhibitor (PD, 6.9 weeks) | Sorafenib (PR, 50.4 weeksb) |
Case 2 HCC (Child-Pugh A Hepatitis B) | Oncolytic vaccine and sorafeniba (PD, 11.7 weeks) | FGFR inhibitor and PD-1 inhibitor (SD, 21.1 weeks) | Lenvatinib (PR, 18.0 weeks) Ramucirumab (PR, 24.0 weeks) XELOX (PD, 4.0 weeks) |
Case 3 HCC (Child-Pugh A Hepatitis B) | None | PD-L1 inhibitor (SD, 31.0 weeks) | Sorafenib (PR, 14.7 weeks); Lenvatinib (PD, 7.0 weeks) Regorafenib (PD, 4.0 weeks) |
Case 4 HCC (Child-Pugh A Hepatitis C) | None | PD-L1 inhibitor (SD, 12.2 weeks) | Sorafenib (CR, 65.4 weeksb) |
Case 5 HCC (Child-Pugh A Hepatitis B) | None | PD-L1 inhibitor CTLA-4 inhibitor (PD, 16.4 weeks) | Lenvatinib (PR, 20.4 weeks) Pan-HER inhibitor (PD, 3.1 weeks) FGFR inhibitor (NE, 2.6 weeks) |
Case 6 Rectal cancer | FOLFOX-Cetuximab ➔ deGramont-Cetuximab (PR, 55.9 weeks) FOLFIRI-Bevacizumab (PR, 55.6 weeks) Regorafenib (NE) FOLFIRI/Pan-Her inhibitor (NE) TAS-102 (PD, 9.6 weeks) | PD-1 inhibitor and MEK inhibitor (SD, 12.1 weeks) | FOLFIRI and cetuximab (PR, 39.1 weeks) FOLFOX and panitumumab (NE) |